Little doubt remains about the value of lipid-lowering therapy since publication of the results of large, randomized, controlled trials that show decreased total, as well as coronary, mortality with the use of statins for primary and secondary prevention of coronary artery disease, All of the available statins are effective a safe, but they vary greatly in terms of cost-effectiveness.
Fluvastatin has been determined to be a cost-effective therapeutic agent in the large proportion of the population with mild-to-moderate dyslipidemia who fit treatment guidelines of the National Cholesterol Education Program (NCEP).
Aforvastatin and simvastatin are cost-effective for the relatively smaller number of patients who require greater reductions in cholesterol.
Mots-clés Pascal : Cardiopathie coronaire, Traitement, Chimiothérapie, Inhibiteur enzyme, Hydroxymethylglutaryl-CoA reductase, Oxidoreductases, Enzyme, Coût, Economie santé, Efficacité traitement, Critère décision, Dyslipémie, Facteur risque, Forme pharmaceutique, Homme, Prévention, Lipide, Appareil circulatoire pathologie, Hypolipémiant, Métabolisme pathologie
Mots-clés Pascal anglais : Coronary heart disease, Treatment, Chemotherapy, Enzyme inhibitor, Hydroxymethylglutaryl-CoA reductase, Oxidoreductases, Enzyme, Costs, Health economy, Treatment efficiency, Decision criterion, Dyslipemia, Risk factor, Dosage form, Human, Prevention, Lipids, Cardiovascular disease, Antilipemic agent, Metabolic diseases
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0074237
Code Inist : 002B02N. Création : 31/05/1999.